The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 82.70
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 4.00 (5.006%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 82.70
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kerry announces intent to acquire Biosearch Life

15 Feb 2021 08:13

RNS Number : 0878P
Kerry Group PLC
15 February 2021
 

 

15 February 2021

LEI: 635400TLVVBNXLFHWC59

 

KERRY GROUP

Kerry Group plc announces its intention to acquire Biosearch Life

Dublin, IRELAND: Kerry Group plc has announced its intention to acquire the Spanish company Biosearch Life.

Based in Granada, Spain and employing over 150 employees, Biosearch Life is a leader in the nutraceutical and functional food sectors. The company has an extensive range of probiotics and is a recognised leader in premium probiotics obtained from human breast milk (Hereditum® brand), scientifically backed innovative botanical extracts (Exxentia®) and natural omega-3 (Eupoly-3® brand).

The acquisition is envisaged to be completed by means of a friendly public tender offer for the shares of Biosearch Life addressed to all of its shareholders and is subject to the prior approval of the Spanish National Securities Markets Commission and, upon its approval, to the acceptance of the offer by Biosearch Life's shareholders. Grupo Lactalis Iberia, S.A., main shareholder of Biosearch Life, has irrevocably undertaken to tender its entire stake representing 29.5% of the share capital of the company into the offer.

For further details on the terms and conditions of the offer please see the offer announcement published on the following link: verDoc.axd (cnmv.es)

ENDS

 

CONTACT INFORMATION

 

 

 

 

 

Media

 

 

Catherine Keogh, VP Corporate Affairs & Communications

 

 

+353 45 930188 | corpaffairs@kerry.com

 

 

 

 

 

Investor Relations

 

 

Marguerite Larkin, Chief Financial Officer

 

 

+353 66 7182292 | investorrelations@kerry.ie

 

 

 

 

 

William Lynch, Head of Investor Relations

 

 

+353 66 7182292 | investorrelations@kerry.ie

 

 

 

 

 

Website

 

 

www.kerrygroup.com

 

 

 

 

 

About Kerry

Kerry, the Taste & Nutrition company, offers solutions that nourish lives all over the world. From humble beginnings as an Irish dairy co-operative, Kerry has grown into a large international food industry leader, with offices in 32 countries, 149 manufacturing facilities and more than 26,000 employees globally, including over 1,000 food scientists. It brings to the table a strong food heritage, coupled with over 40 years of experience, global insights and market knowledge, culinary and applications expertise, as well as a range of unique solutions that anticipate and address customers' needs. For more information, visit kerrygroup.com.

 

About Biosearch Life

Biosearch Life is a biotechnology company focused on providing innovative solutions worldwide in the pharmaceutical, nutraceutical and functional food sectors providing a wide range of high-quality products and services which revolve around the concept of a healthy life. The company has a range of products in three primary areas: probiotics, omega-3 fatty acids and botanical extracts. Biosearch Life distributes its products across Europe, Asia and the USA and has an average annual workforce of over 150 employees. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQSFSSAIEFSEFE
Date   Source Headline
3rd May 202412:10 pmRNSKerry Announces €300m Share Buyback Programme
2nd May 20244:14 pmRNSResult of AGM
2nd May 20247:00 amRNSQ1 Interim Management Statement 2024
1st May 202410:05 amRNSTotal Voting Rights
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 202412:42 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20249:48 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 202411:55 amRNSNotice of AGM
28th Mar 20247:00 amRNSTransaction in Own Shares
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 202410:30 amRNSAnnual Financial Report
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 202412:42 pmRNSDirector/PDMR Shareholding
7th Mar 202412:39 pmRNSDirector/PDMR Shareholding
7th Mar 202412:34 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.